Prior antibiotic administration disrupts outcomes of PD-1 blockade in advanced gastric cancer by altering gut microbiome and systemic immune response
We thoroughly uncovered clinical and translational evidence that pATB use can influence treatment outcomes of ICI treatment, highlighting the significance of such practice among patients with AGC. Overall design: We analyzed circulating immune cells and gut microbiota via single-cell (sc) RNA and TCR sequencing